Trump Order Gives Psychedelic Therapy a Boost

Trump's April 2026 executive order accelerates psychedelic therapy research and FDA approval pathways, allocates $50m to state research efforts, and signals government backing for psilocybin and MDMA trials. Experts caution that expanded access requires larger clinical trials, trained clinician networks, standardised reimbursement frameworks, and science-driven regulatory decisions rather than political momentum.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.